Tinzaparin Injectable Solution — Competitive Intelligence Brief

Tinzaparin Injectable Solution (Tinzaparin Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low molecular weight heparin. Area: Cardiovascular.

phase 3 Low molecular weight heparin Coagulation factors (IIa and Xa) Cardiovascular Small molecule

Target snapshot

Tinzaparin Injectable Solution (Tinzaparin Injectable Solution) — Queen Mary University of London. Tinzaparin is a low molecular weight heparin that works by inhibiting coagulation factors to prevent blood clot formation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tinzaparin Injectable Solution TARGET	Tinzaparin Injectable Solution	Queen Mary University of London	phase 3	Low molecular weight heparin	Coagulation factors (IIa and Xa)
Lovenox (Preservative Free)	ENOXAPARIN SODIUM	Sanofi	marketed	Low Molecular Weight Heparin	Antithrombin-III	1993-01-01
half amount low molecular weight heparin	half amount low molecular weight heparin	Beijing Anzhen Hospital	marketed	Anticoagulant (low molecular weight heparin)	Antithrombin III (indirect target); Factor Xa and Factor IIa (downstream targets)
Fragmin	Dalteparin Sodium	Pfizer Inc.	marketed	Low molecular weight heparin (LMWH)	Factor Xa and thrombin
UFH	UFH	VarmX B.V.	phase 3	Low molecular weight heparin	Antithrombin III
Tinzaparin (Leo)	Tinzaparin (Leo)	Aalborg University Hospital	phase 3	Low molecular weight heparin	Factor Xa, Thrombin
intermediate dose Enoxaparin/ unfractionated heparin	intermediate dose Enoxaparin/ unfractionated heparin	Rajaie Cardiovascular Medical and Research Center	phase 3	Low molecular weight heparin	Antithrombin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low molecular weight heparin class)

1. Aalborg University Hospital · 1 drug in this class
2. Queen Mary University of London · 1 drug in this class
3. Rajaie Cardiovascular Medical and Research Center · 1 drug in this class
4. VarmX B.V. · 1 drug in this class